Anticancer profiling: DCffer® method
Fluofarma developed DCffer® method, a powerful approach to compare and profile your anti-cancer drugs.
Methods
This innovative method compares your drugs to a proprietary functional
signature database of reference anti-cancer compounds.
Step 1: Testing of your drugs against one
among 20 different human cancer cell lines by simultaneously detecting
4 key parameters: DNA strand breaks, proliferation inhibition,
apoptosis and cytolysis.
Step 2: Determination of a unique signature integrating potency and efficacy at different time points for each parameter.
Step 3: Profiling of your drug comparing its signature with a database of reference anticancer compounds by cluster analysis.
Example of DCffer® method
DCffer® method shows that the compound X has an innovative mechanism of action
whereas compounds Y and Z are respectively closed from Cisplatin and Docetaxel
mechanisms of action.
Breaking news
Scientific Publication
Fluofarma is glad to announce a new scientific publication in the journal Biochimica et Biophysica Acta - Molecular Cell Research.Read more [+]
IFSCC 2008
Fluofarma will be attending IFSCC 2008, in Barcelona, from October 6th to 9th.Read more [+]
INVITOX 2008
Fluofarma will be attending the INVITOX 2008 meeting, in Stockholm from September 25th to 28th.Read more [+]
EuroBio 2008
Fluofarma will be attending EuroBio 2008, in Paris from October 7th to 9th.Read more [+]
SMi's Cell-Based Assays 2008
Fluofarma will be attending SMi's Cell-Based Assays conference, in London from November 19th to 20th.Read more [+]
GDDI Forum 2009
Fluofarma will be attending Global Discovery & Development Innovation Forum 2009, in London, from March 2nd to 3rd.Read more [+]
FOCUS: Anticancer drugs profiling
Fluofarma has developed DCffer® method, a powerful approach to
compare and profile your anti-cancer drugs. Read
more [+]